SI-BONE Inc Director Davis Timothy E JR Sells 9,900 Shares
On January 2, 2024, Davis Timothy E JR, a Director at SI-BONE Inc (NASDAQ:SIBN), completed the sale of 9,900 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing.
SI-BONE Inc is a medical device company that focuses on the design, development, and commercialization of musculoskeletal devices for patients with spine disorders. The company's flagship product, the iFuse Implant System, is used in minimally invasive surgery to treat sacroiliac joint dysfunction.
Over the past year, the insider has sold a total of 9,900 shares and has not made any purchases of SI-BONE Inc stock. The insider transaction history for SI-BONE Inc shows a pattern of 37 insider sells and no insider buys over the past year.
On the date of the insider's recent sale, shares of SI-BONE Inc were trading at $20.93, resulting in a market capitalization of $833.916 million.
The stock's price-to-GF-Value ratio stood at 0.83, with a GF Value of $25.24, indicating that SI-BONE Inc was modestly undervalued at the time of the sale.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
